multiple-sclerosis
1 cases — ← All topics
| Case | Title | Lower Court | Docketed | Status | Flags | Tags | Question Presented |
|---|---|---|---|---|---|---|---|
| 21-1567 | Biogen International GmbH, et al. v. Mylan Pharmaceuticals Inc. | Federal Circuit | 2022-06-15 | Denied | Amici (2) | 35-usc-112 effective-dose efficacy-requirement federal-circuit multiple-sclerosis patent patent-law patent-specification statutory-interpretation written-description | Is 35 U.S.C. § 112's written-description requirement met when the specification describes the invention? |